Now showing items 1-3 of 3
The Association between the UGT2B17 Gene Deletion and Menopause-Related Quality of Life in Postmenopausal Women in the CCTG MAP.3 Breast Cancer Chemoprevention Trial
Background: Mammary Prevention.3 (MAP.3) was a randomized placebo controlled trial of exemestane for breast cancer prevention. Participants commonly experienced vasomotor symptoms, such as hot flashes. Exemestane is ...
Comparing the Responsiveness of two Health-Related Quality of Life Instruments in a Phase III Randomized Clinical Trial of Men With Prostate Cancer (NCIC CTG PR.3): the EORTC QLQ-C30+3 With PR17 Trial Specific Checklist Versus the FACT-P
Background: The EORTC QLQ-C30 and the FACT are two commonly used Health-Related Quality of Life (HRQL) instruments in cancer clinical trials, but there is limited data comparing them. The NCIC CTG PR.3 clinical trial ...
Assessing the Effectiveness of Palliative Chemotherapy for Non-Small Cell Lung Cancer: a Phase IV Study of Patients Treated at Ontario’s Cancer Centres
Background: Randomized controlled trials (RCTs) are the gold standard for assessing the efficacy of a medical treatment. However, the efficacy demonstrated by trials does not automatically translate into a comparable ...